dc.contributor.author
Ritschl, Paul Viktor
dc.contributor.author
Günther, Julia
dc.contributor.author
Hofhansel, Lena
dc.contributor.author
Ernst, Stefanie
dc.contributor.author
Ebner, Susanne
dc.contributor.author
Sattler, Arne
dc.contributor.author
Weiß, Sascha
dc.contributor.author
Weissenbacher, Annemarie
dc.contributor.author
Oberhuber, Rupert
dc.contributor.author
Cardini, Benno
dc.contributor.author
Öllinger, Robert
dc.contributor.author
Biebl, Matthias
dc.contributor.author
Denecke, Christian
dc.contributor.author
Margreiter, Christian
dc.contributor.author
Resch, Thomas
dc.contributor.author
Schneeberger, Stefan
dc.contributor.author
Maglione, Manuel
dc.contributor.author
Kotsch, Katja
dc.contributor.author
Pratschke, Johann
dc.date.accessioned
2021-10-26T12:47:15Z
dc.date.available
2021-10-26T12:47:15Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/32406
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-32131
dc.description.abstract
Due to the lack of suitable organs transplant surgeons have to accept unfavorable extended criteria donor (ECD) organs. Recently, we demonstrated that the perfusion of kidney organs with anti-human T-lymphocyte globulin (ATLG) prior to transplantation ameliorates ischemia-reperfusion injury (IRI). Here, we report on the results of perioperative ATLG perfusion in a randomized, single-blinded, placebo-controlled, feasibility trial (RCT) involving 30 liver recipients (LTx). Organs were randomly assigned for perfusion with ATLG/Grafalon (AP) (n = 16) or saline only (control perfusion = CP) (n = 14) prior to implantation. The primary endpoint was defined as graft function reflected by aspartate transaminase (AST) values at day 7 post-transplantation (post-tx). With respect to the primary endpoint, no significant differences in AST levels were shown in the intervention group at day 7 (AP: 53.0 ± 21.3 mg/dL, CP: 59.7 ± 59.2 mg/dL, p = 0.686). Similarly, exploratory analysis of secondary clinical outcomes (e.g., patient survival) and treatment-specific adverse events revealed no differences between the study groups. Among liver transplant recipients, pre-operative organ perfusion with ATLG did not improve short-term outcomes, compared to those who received placebo perfusion. However, ATLG perfusion of liver grafts was proven to be a safe procedure without the occurrence of relevant adverse events.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
liver transplantation
en
dc.subject
organ perfusion
en
dc.subject
organ pretreatment
en
dc.subject
machine perfusion
en
dc.subject
polyclonal antibody
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Perioperative Perfusion of Allografts with Anti-Human T-lymphocyte Globulin Does Not Improve Outcome Post Liver Transplantation—A Randomized Placebo-Controlled Trial
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
2816
dcterms.bibliographicCitation.doi
10.3390/jcm10132816
dcterms.bibliographicCitation.journaltitle
Journal of Clinical Medicine
dcterms.bibliographicCitation.number
13
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
10
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34202355
dcterms.isPartOf.eissn
2077-0383